Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price traded down 5.8% on Tuesday . The company traded as low as $3.27 and last traded at $3.27, with a volume of 147,047 shares changing hands. The stock had previously closed at $3.47.

RGLS has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price target on shares of Regulus Therapeutics in a research note on Tuesday, June 7th. Chardan Capital lifted their price target on Regulus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, June 7th. FBR & Co reaffirmed a “buy” rating and issued a $30.00 price target on shares of Regulus Therapeutics in a research note on Thursday, June 2nd. BMO Capital Markets reaffirmed a “buy” rating on shares of Regulus Therapeutics in a research note on Monday, May 2nd. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Regulus Therapeutics in a research note on Monday, May 2nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Regulus Therapeutics currently has an average rating of “Buy” and an average price target of $10.42.

The firm has a 50 day moving average price of $4.52 and a 200 day moving average price of $6.02. The firm’s market cap is $181.04 million.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.07. Equities research analysts anticipate that Regulus Therapeutics Inc. will post ($1.54) earnings per share for the current year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.